Leaflet LIRAGLUTID CIPLA 6mg / ml solution for injection in pre-filled pen
Indicated for: type 2 diabetes mellitus; weight management
Route of administration: injectable
Substance: liraglutide (GLP-1 receptor agonist)
ATC: A10BJ02 (Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Glucagon-like peptide-1 (GLP-1) analogues)
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Liraglutide is a medication used for the treatment of type 2 diabetes and obesity. It is a glucagon-like peptide-1 (GLP-1) analog that works by stimulating insulin secretion, reducing glucagon secretion, and slowing gastric emptying, thereby lowering blood sugar levels and reducing appetite.
Liraglutide is administered as a subcutaneous injection, usually once daily, and is used either for blood sugar control in patients with type 2 diabetes or for weight loss in patients with obesity or overweight associated with other conditions (such as hypertension or dyslipidemia).
Side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, or, in rare cases, pancreatitis. It may also cause appetite suppression and weight loss. It is important to use the medication as prescribed by a doctor, and patients should be monitored to prevent complications.
General data about LIRAGLUTID CIPLA 6mg / ml
- Substance: liraglutide
- Date of latest medicines list: 01-01-2026
- Product code: W71578001
- Concentration: 6mg / ml
- Pharmaceutical form: solution for injection in pre-filled pen
- Quantity: 2
- Product type: Generic medicine
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.